Cardiol Therapeutics Inc Class A (CRDL : TSX)
Common Stock
$1.50
CAD
+0.06 (4.17%)
Last updated: 2026-07-13
CRDL
Cardiol Therapeutics Inc Class A
WealthAwesomePerformance
1 Day
+4.17%
1 Week
-1.96%
1 Month
+2.74%
YTD
+10.29%
Key Statistics
Market Cap
$165.99M
52W High
$2.33
52W Low
$1.23
P/E Ratio
-
50 Day MA
$1.64
200 Day MA
$1.54
Beta
0.51
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/13/2026 | $1.44 | $1.52 | $1.44 | $1.50 | $1.50 | 87,301 |
| 7/10/2026 | $1.44 | $1.44 | $1.37 | $1.44 | $1.44 | 52,066 |
| 7/9/2026 | $1.44 | $1.46 | $1.42 | $1.46 | $1.46 | 60,043 |
| 7/8/2026 | $1.46 | $1.46 | $1.40 | $1.44 | $1.44 | 35,068 |
| 7/7/2026 | $1.53 | $1.53 | $1.42 | $1.47 | $1.47 | 73,624 |
| 7/6/2026 | $1.53 | $1.57 | $1.51 | $1.53 | $1.53 | 81,936 |
| 7/3/2026 | $1.50 | $1.53 | $1.50 | $1.53 | $1.53 | 5,927 |
| 7/2/2026 | $1.48 | $1.55 | $1.46 | $1.54 | $1.54 | 94,634 |
| 6/30/2026 | $1.48 | $1.53 | $1.47 | $1.49 | $1.49 | 28,900 |
| 6/29/2026 | $1.52 | $1.52 | $1.44 | $1.49 | $1.49 | 64,855 |
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+300.0% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.1%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.25 – C$1.60 |
| 60 trading days | C$1.33 | C$1.12 – C$1.58 |
| 90 trading days | C$1.25 | C$1.02 – C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-35.57M
- Profit Margin
- 0.00%
- ROE (TTM)
- -173.96%
- EPS (Diluted)
- -0.39
- Book Value
- 0.22
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CRDL
Articles Featuring CRDL.TO
Latest articles and analysis covering CRDL.TO
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today
Cardiol Therapeutics Inc Class A has experienced a significant stock price increase of 10.67% today, driven by positive investor sentiment surrounding its innovative cardiac treatments.
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday?
Cardiol Therapeutics Inc Class A (CRDL.TO) has seen a 4.17% increase in its stock price today, as trading volume surged to more than double its 20-day average. This comes amid a backdrop of steady performance and no major news announcements this week.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A (CRDL.TO) has surged by 3.47% in today's trading session, closing at CA$1.49. This uptick is attributed to the company's recent financing activities aimed at supporting its clinical trials, particularly the MAVERIC Phase III trial.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A experienced a significant drop in stock price, closing down 3.42% in the latest trading session. Investors may be concerned about the company's future prospects despite recent operational updates.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A saw a significant drop in its stock price today, closing at CA$1.41. This decline of 4.08% raises questions about the company's future prospects amidst a lack of recent positive developments.
Why Cardiol Therapeutics Inc Class A stock is plummeting today
Cardiol Therapeutics Inc Class A saw its stock price drop by 5.88% in the latest trading session, closing at CA$1.44. This decline raises questions about the company's market position and future prospects.
Why Cardiol Therapeutics Inc Class A stock is gaining today
Cardiol Therapeutics Inc Class A is on the rise, with shares increasing by 1.63% to CA$1.55. This gain may signal investor optimism regarding the company's future prospects and recent operational updates.
Why Cardiol Therapeutics Inc Class A stock is tanking today
Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a 0.65% drop in stock price today, closing at CA$1.53. This decline raises concerns about investor confidence amidst a lack of significant news to drive the stock's performance.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A (CRDL.TO) faced a downturn in its stock price, closing at CA$1.47 after a 2.65% drop. Investors are left questioning the stability of this biotech firm amid a lack of recent positive news.
Why Cardiol Therapeutics Inc Class A stock is tanking today
Cardiol Therapeutics Inc Class A (CRDL.TO) faced a significant setback today, closing down 1.32% at CA$1.49. This decline raises questions about investor confidence in the company's future.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a 2.31% increase in its stock price, driven by investor optimism linked to its clinical advancements and upcoming presentations.
Why Cardiol Therapeutics Inc Class A stock is gaining today
Cardiol Therapeutics Inc Class A (CRDL.TO) is gaining traction in the market, with a 0.67% increase in its stock price. The company's active involvement in industry events and clinical trials is boosting investor confidence.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A has seen its stock rise by 4.08%, closing at CA$1.53. This increase is attributed to positive developments in the company's clinical trial programs and strategic initiatives.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A saw its stock slide 3.18% today, closing at CA$1.52. With no significant news driving the decline, investors are left to ponder the implications for the company's future.
